Nuvectis Pharma, Inc. NVCT
Institutional shares held
1.9 Million
0
calls
0
puts
Total value of holdings
$19.9M
$0
calls
$0
puts
Market Cap
$153M
14,642,500
Shares Out.
Institutional ownership
13.01%
# of Institutions
32
We take great care to ensure that the data presented and summarized in this overview for Nuvectis Pharma, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NVCT
View all-
Ronit Capital LLP563KShares$5.88 Million5.37% of portfolio
-
Baldwin Brothers LLC356KShares$3.72 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA325KShares$3.4 Million0.0% of portfolio
-
Marshall Wace, LLP London, X0125KShares$1.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY83.4KShares$872,4890.0% of portfolio
-
Geode Capital Management, LLC Boston, MA79.2KShares$828,8810.0% of portfolio
-
Forbes J M & CO LLP59KShares$617,1400.03% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA45.6KShares$477,0490.0% of portfolio
-
Gsa Capital Partners LLP London, X034.8KShares$363,4950.01% of portfolio
-
Qube Research & Technologies LTD London, X030.6KShares$320,0130.0% of portfolio
Latest Institutional Activity in NVCT
Top Purchases
Top Sells
About NVCT
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Insider Transactions at NVCT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 07
2025
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
240,000
+7.68%
|
$1,200,000
$5.0 P/Share
|
|
Jan 02
2025
|
Michael J. Carson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
51,000
+26.85%
|
-
|
|
Jan 02
2025
|
Enrique Poradosu Chief Science & Business Off |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+8.3%
|
-
|
|
Jan 02
2025
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+8.37%
|
-
|
|
Jan 02
2025
|
Ron Bentsur Chairman & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
250,000
+6.63%
|
-
|
|
Dec 24
2024
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
4,500
+0.14%
|
$18,000
$4.65 P/Share
|
|
Dec 13
2024
|
Marlio Charles Mosseri > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
17,000
+0.65%
|
$68,000
$4.7 P/Share
|
|
Nov 19
2024
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
2,000
+0.13%
|
$8,000
$4.99 P/Share
|
|
Nov 15
2024
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
20,000
+0.61%
|
$80,000
$4.92 P/Share
|
|
Nov 07
2024
|
Michael J. Carson Vice President, Finance |
SELL
Open market or private sale
|
Direct |
2,755
-3.04%
|
$22,040
$8.16 P/Share
|
|
Jun 13
2024
|
James F Oliviero Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+34.16%
|
-
|
|
Jun 13
2024
|
Kenneth Hoberman Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+22.53%
|
-
|
|
Jun 13
2024
|
Matthew L. Kaplan Director |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+26.37%
|
-
|
|
May 14
2024
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
1,940
+0.06%
|
$11,640
$6.74 P/Share
|
|
May 10
2024
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
2,000
+0.06%
|
$12,000
$6.4 P/Share
|
|
May 10
2024
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Open market or private purchase
|
Direct |
1,113
+0.07%
|
$6,678
$6.32 P/Share
|
|
May 10
2024
|
Enrique Poradosu Chief Science & Business Off |
BUY
Open market or private purchase
|
Direct |
500
+0.03%
|
$3,000
$6.29 P/Share
|
|
Mar 18
2024
|
Ron Bentsur Chairman & CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+0.15%
|
$50,000
$10.29 P/Share
|
|
Jan 04
2024
|
Michael J. Carson Vice President, Finance |
BUY
Grant, award, or other acquisition
|
Direct |
34,567
+27.6%
|
-
|
|
Jan 03
2024
|
Shay Shemesh Chief Dev. & Ops. Officer |
BUY
Grant, award, or other acquisition
|
Direct |
130,000
+8.02%
|
-
|
Last 12 Months Summary
Buy / Acquisition
980K
Shares
From
11
Insiders
| Grant, award, or other acquisition | 691K shares |
|---|---|
| Open market or private purchase | 289K shares |
Sell / Disposition
2.76K
Shares
From
1
Insiders
| Open market or private sale | 2.76K shares |
|---|